Participate in Research:
A randomized placebo-controlled trial of ARBaclofen vs. placebo in the treatment of children and adolescents with ASD

Principal Investigator:
Dr. Muhammad Ayub

Queen’s University:
Psychiatry Department

The Province of Ontario Neurodevelopmental Disorders (POND) Network is researching genes, the brain, and behaviour to find potential treatments in autism spectrum disorder (ASD).

What is this study about?
We are currently investigating a study drug called arbaclofen to improve social functioning in children and teens with Autism!

Who can participate?
We are looking for:
• Children and teens between 5 and 17 years old
• Diagnosed with an autism spectrum disorder (ASD)
• Able to tolerate bloodwork

What’s involved?
• This study is comparing arbaclofen against placebo for improving social & global function, and communication
• The trial is 18 weeks long
• All participants who complete the study are eligible for the open-label phase (where all participants receive the study drug)
• There are 9 study visits
• Study procedures include height and weight, bloodwork, EEG, and questionnaires

Potential Benefits?
• Arbaclofen may help improve social functioning
• This research will help other children and families with ASD

Potential Risks?
• The most common side effects are sedation (tiredness) and upset stomach

Participants will receive a gift card at each visit to thank them for their time.

CONTACT INFORMATION:
For more information, contact Jennifer Lalonde at 613-548-4417 ext. 1111

Date Posted:
Version Date:
[V.2] 30Oct2018